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n Abstract
Background and Objective: Drug-induced anaphylaxis is an unpredictable and potentially fatal adverse drug reaction. The aim of this study 
was to identify the causes of drug-induced anaphylaxis in Portugal. 
Methods: During a 4-year period a nationwide notification system for anaphylaxis was implemented, with voluntary reporting by allergists. 
Data on 313 patients with drug anaphylaxis were received and reviewed. Statistical analysis included distribution tests and multiple logistic 
regression analysis to investigate significance, regression coefficients, and marginal effects.
Results: The mean (SD) age of the patients was 43.8 (17.4) years, and 8.3% were younger than 18 years. The female to male ratio was 
2:1. The main culprits were nonsteroidal anti-inflammatory drugs (NSAIDs) (47.9% of cases), antibiotics (35.5%), and anesthetic agents 
(6.1%). There was a predominance of mucocutaneous symptoms (92.2%), followed by respiratory symptoms (80.4%) and cardiovascular 
symptoms (49.0%). Patients with NSAID-induced anaphylaxis showed a tendency towards respiratory and mucocutaneous manifestations. 
We found no significant associations between age, sex, or atopy and type of drug. Anaphylaxis recurrence was observed in 25.6% of 
cases, and the risk was higher when NSAIDs were involved. 
Conclusions: NSAIDs were the most common cause of anaphylaxis in this study and were also associated with a higher rate of recurrence. 
We stress the need for better therapeutic management and prevention of recurring episodes of drug-induced anaphylaxis.
Key words: Anaphylaxis. Drug hypersensitivity. Notification. Portuguese survey.
n Resumen
Antecedentes: La anafilaxia inducida por medicamentos es una reacción adversa impredecible y potencialmente fatal. El objetivo de este 
estudio fue identificar las causas de la misma en Portugal.
Método: Durante un periodo de 4 años fue desarrollado un sistema de notificación nacional de anafilaxia enfocado al informe voluntario de 
los alergólogos. Se recopilaron 313 casos de pacientes con anafilaxia por medicamentos. El análisis estadístico incluyó test de distribución 
y regresión logística múltiple para analizar la significación y los coeficientes de regresión y efectos marginales.
Resultados: La edad media de los pacientes fue de 43.8 ± 17.4 años, 8.3% menores de 18 años. La relación mujer/varón fue de 2:1. El grupo 
más frecuentemente implicado fue el de los analgésicos antiinflamatorios no esteroideos (AINEs), seguido de los antibióticos y anestésicos 
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Introduction
Adverse drug reactions are a serious public health problem in 
both inpatient and outpatient settings. They are associated with high 
morbidity and socioeconomic costs and are also potentially fatal, 
with an inpatient mortality of 0.05% to 0.19% [1]. Approximately 
20% of adverse drug reactions, which are mediated by allergic 
or nonallergic mechanisms, are designated hypersensitivity 
reactions. 
Anaphylaxis is a severe, potentially fatal event. It is an 
acute systemic hypersensitivity reaction with simultaneous 
involvement of several organs, particularly the skin, the 
respiratory tract, and the gastrointestinal and/or the cardiovascular 
system. The severity of the reaction varies, and is classified as 
grade I to IV on the Ring and Messmer scale [2]. The diagnostic 
and treatment criteria for anaphylaxis were recently revised to 
standardize the concepts used [3,4].
Anaphylactic reactions associated with drugs can be due to 
IgE antibody–mediated immunological reactions to the drug or 
to a metabolite or excipient. Reactions with similar symptoms, 
however, can be non-immunologically mediated. This condition 
was formerly called non-immunological anaphylaxis [4]. 
According to a study of primary healthcare data from 
the United Kingdom the annual incidence of anaphylaxis is 
8.4 cases per 100 000 individuals in the general population, 
and the most frequent causes are insect venoms (32%), drugs 
(30%), and foods (22%) [5]. In a recent report based on the 
Latin American Survey of Anaphylaxis, the main causes of 
anaphylactic reactions were drugs (31.2%), foods (23.3%), 
and insect stings (14.9%) [6].
In a retrospective study performed in an inpatient 
immunoallergology department in Portugal, the main agents 
causing anaphylactic reactions in adults were drugs (66%), 
iodinated contrast media (ICM) (19%), foods (13%), and 
hymenoptera venoms (2%) [7]. Finally, in 2 studies of 
outpatient children in Portugal, the most common causes of 
anaphylaxis were found to be foods, drugs, and latex [8,9].
Geographic factors and prescription patterns influence the 
rate of anaphylaxis to different classes of drugs. 
A recent meta-analysis of 18 international epidemiological 
studies on drug-induced anaphylaxis in adults and children 
published from 1994 to 2009 reported that it was impossible 
to quantify the rate and mortality of drug-induced anaphylaxis 
because of differences in methodology and definitions of 
anaphylaxis [10]. In the majority of cases diagnosis was based 
on clinical examination and epidemiological data rather than on 
confirmation of a cause-effect relationship or the identification 
of underlying immunological mechanisms. A predominance of 
cases were seen in males aged under 15 years and the highest 
rate was seen in adults aged 55 to 84 years (3.8/100 000 
individuals) [10]. Drugs are considered the main trigger of 
adult-age anaphylaxis, particularly in individuals aged over 65 
years [4,11]. Drugs were reported as the main cause of fatal 
anaphylaxis in this age group in the United Kingdom, New 
Zealand, and Australia [10]. 
The above meta-analysis also concluded that penicillin 
and general anesthetic agents were the most common causes 
of IgE-mediated anaphylactic reactions, while nonsteroidal 
anti-inflammatory drugs (NSAIDs) and ICM were the most 
common causes of non-immunological anaphylaxis [10]. 
In addition, inpatients have also been found to be at greater 
risk of anaphylaxis due to streptokinase and plasma and its 
derivatives and at lower risk of anaphylaxis due to NSAIDs 
and antibiotics [12].
The difficulty in confirming a diagnosis of anaphylaxis 
lies in the lack of standardized tests for studying reactions to 
the majority of drugs and the limitations of challenge tests in 
patients with potentially fatal reactions.  
The severity of the anaphylactic reaction is related to the 
type of drug involved, the individual’s degree of sensitivity, 
and other factors such as age, genetic background, co-infection 
or inflammatory disease, exercise, stress, and concomitant 
treatment [4,9]. Asthma and other chronic respiratory diseases, 
cardiovascular disease, mastocytosis, and the co-administration 
of β-blockers or angiotensin-converting-enzyme inhibitors 
seem to be risk factors for severe or fatal reactions [3,13,14].
The true rate of drug anaphylaxis in Portugal is unknown as 
cases are not systematically registered, but a recent publication 
of drug-induced anaphylaxis cases reported to the Portuguese 
Pharmacovigilance Authority shows a tendency towards an 
increase in recent years [15].
The aim of this study was to contribute to a better 
understanding of the causes of drug-induced anaphylaxis in 
Portugal based on a study of anaphylaxis cases reported by 
immunoallergology departments over a 4-year period. 
Methods
The Portuguese Society of Allergology and Clinical Immunology 
(SPAIC) implemented a national anaphylaxis notification system 
over a 4-year period (January 2007-December 2010). 
en 47.9%, 35.5% y 6.1% de los casos respectivamente. Se observó un predominio de los síntomas mucocutáneos (92.2%), seguidos 
de los respiratorios (80.4%) y cardiovasculares (49.0%). Los pacientes con anafilaxia por AINEs mostraban más síntomas respiratorios 
y mucocutáneos. No se encontró asociación entre edad, género y atopia con los diferentes grupos de medicamentos. La recurrencia de 
anafilaxia se observó en el 25.6% de los casos, con un riesgo incrementado cuando los AINEs eran los responsables. 
Conclusiones: En este estudio, los AINEs fueron los medicamentos más frecuentemente implicados en las reacciones de anafilaxia y 
mostraron más frecuencia de reincidencia de las reacciones. Es importante evaluar bien los tratamientos y prevenir la reincidencia de 
anafilaxia por medicamentos.
Palabras clave: Anafilaxia. Hipersensibilidad a medicamentos. Encuesta portuguesa.
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Anaphylaxis was diagnosed according to the criteria 
published by the American Academy of Asthma, Allergy and 
Immunology (AAAAI), the European Academy of Allergy 
and Clinical Immunology (EAACI), and the World Allergy 
Organization (WAO) [3,4].
All members of SPAIC were invited to participate in the 
project and asked to use a specially designed questionnaire 
(Figure 1) to report all cases of drug-induced anaphylaxis 
(“at least 1 episode of a severe systemic reaction”) seen in 
their departments. The questionnaires were sent by letter, fax, 
e-mail, or through an online system on the SPAIC website. 
All notifications received were evaluated and validated by 
members of the SPAIC Drug Allergy Interest Group. After a 
preliminary data analysis, it was decided to complement this 
questionnaire with further data. When necessary, clarification 
was sought from the notifying person. 
A diagnosis of drug-induced anaphylaxis was confirmed 
by allergists based on the consensus statement published by 
the European Network of Drug Allergy - ENDA/EAACI [16].
The information in the questionnaire was complemented 
with further data in a subsample of 282 cases (90.0%). 
Additional information included drug administration route, 
time between drug administration and onset of symptoms, 
setting (inpatient or outpatient), and the presence of atopy.
Population
Questionnaires containing information on 313 patients with 
a clinical history of drug-induced anaphylaxis were received 
from 41 Portuguese immunoallergology specialists.
Statistical Analysis
The results are given as the frequency of positive answers 
relative to the total number of valid responses. Multivariate 
logistic regression analysis was used to evaluate significance 
(P<.05), regression coefficients, and marginal effects. 
Significance was also evaluated using χ2 distribution tests.
Results
We analyzed the cases of 313 patients.  
Forty percent of the population lived in the north of 
Portugal, 38% in the south, 19% in the center, and 3% in the 
Azores and Madeira. 
The mean (SD) age of the patients was 43.8 (17.4) years 
(range, 2-89 years); 8.3% were aged ≥4-18 years; 21.4%, 
≥18-35 years; 58.5%, ≥35-65 years; and 11.8% 65 years 
or older.
There was a majority of female patients (66.1%; male to 
female ratio of 1:2). In the youngest age group, however, there 
were more males than females (ratio of 1.9:1). Forty-three 
percent of the population had a history of allergic disease, 
18.8% had asthma, and 31.6% had rhinitis.
The mean age at the time of the first anaphylactic episode 
was 39.0 (18.2) years (range, 2-89 years). Table 1 shows the 
causes of drug-induced anaphylaxis by age group. 
The 3 main drug groups involved were NSAIDs, 
antibiotics, and anesthetic agents. Tables 2 and 3, respectively, 
show the NSAIDs and antibiotics involved according to age. 
The 19 cases of anaphylaxis induced by anesthetic agents 
were all reported in adults. Local anesthetics were involved in 
2 cases and the anesthetic agent was not identified in 3 cases. In 
the remaining 14 cases, the general anesthetics identified were 
neuromuscular blocking agents (NMBAs) (52.6%), propofol 
(10.5%), and midazolam (10.5%).
Table 4 shows the characteristics of the patients with 
anaphylaxis induced by NASIDs, β-lactam antibiotics, and 
general anesthetics.
No statistically significant differences were found 
between age, atopy, or asthma and type of drug in any of the 
cases, but there was a very high rate of reactions to general 
Figure 1. Anaphylaxis notification report questionnaire.
    Anaphylaxis Notification Report
Patient identification
Name:.__ __ __ (initials)
Date of birth:….../….../…...        Gender: ___ (male / female)                
Residence: ......................................................................................
Cause of anaphylaxis
Food allergy: ___ (yes / no). If yes, which?.......................................
Drug allergy: ___ (yes / no). If yes, which?.......................................
Latex allergy: ___ (yes / no). Latex-fruit syndrome: ___ (yes / no)
Insect sting allergy: ___ (yes / no). If yes, which?..............................
Cold / other physical agent: ___ (yes / no). If yes, which?.................
Idiopathic anaphylaxis: ___ (yes / no)
Other cause: ___ (yes / no). If yes, which?........................................
Description(s) of reaction(s): ….......................................................
......................................................................................................
.......................................................................................................
Date of anaphylaxis (first episode): ….../….../…...
Number of anaphylaxis episodes:.........................
Treatment
Adrenaline: ___ (yes / no). Other therapy: ___ (yes / no) ). If yes,  
which?.............................................................................................
Emergency room visit: ___ (yes / no). 
Hospitalisation: ___ (yes / no).           Fatal outcome: ___ (yes / no). 
Prescription of adrenaline auto-injector: ___ (yes / no).  
Adrenaline  auto-injector use: ___ (yes / no).  
Personal history of allergy
Asthma: ___ (yes / no). Other allergy: ___ (yes / no) ). If yes,  
which?...........................................................................................
Name of notifier:............................................................................
Date of notification: ….../….../…...  Contact (e-mail): .................... 
Imunoallergology Department: ……...............................................
Send to:
SPAIC - Sociedade Portuguesa de Alergologia e Imunologia Clínica
R. Manuel Rodrigues da Silva, 7C - Escritório 1, 1600-503 Lisboa, 
Portugal
Fax: +351 217152428       e-mail: spaic@sapo.pt
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anesthetics in females, with a male to female ratio of 1:4.7. 
Atopy was found in a large percentage of cases (43.1%), 
but was not a risk factor for anaphylaxis to any of the three 
groups of drugs. 
The clinical manifestations were mucocutaneous in 92.2% 
of patients, respiratory in 80.4%, cardiovascular in 49.0%, and 
gastrointestinal in 14.8%. Loss of consciousness occurred in 
13.5% of patients. Simultaneous involvement of 3, 4, and 5 
organ systems was observed in 33.5%, 14.4%, and 2.9% of 
cases, respectively.
Time between drug administration and onset of clinical 
manifestations varied between 5 minutes and 8 hours. The 
majority of patients (88.4%) experienced symptoms within 60 
minutes, and 53.0% of the total group experienced symptoms in 
the first 15 minutes. In 6% of cases, the anaphylactic reactions, 
all related to NSAIDs, were reported after 2 hours: 2 patients 
experienced a reaction 4 hours after the administration of 
nimesulide and another 2 patients experienced a reaction (1 to 
paracetamol and 1 to etoricoxib) after almost 8 hours.
In 45.0% of cases, the anaphylactic reactions occurred 
in a hospital setting. The route of administration was oral 
in 64.4% of cases, intravenous in 23.3%, intramuscular in 
11.1%, and subcutaneous in 0.4%. There was 1 case of rectal 
administration and another of a reaction following intradermal 
testing to amoxicillin.
Emergency hospital assistance was required in 78.3% of 
patients and 31.5% of these were admitted to hospital. Only 
47.7% of patients received treatment with epinephrine. None 
of these reactions was fatal. In 9.0% of cases an epinephrine 
auto-injector was used; use of this injector was significantly 
more common in children (P=.007).
The recurrence rate was 25.6%; 73.8% of patients had 2 
anaphylactic episodes, 15% had 3, 7.5% had 4, and 3.7% had 
5. There were no differences in recurrence of anaphylaxis in 
terms of sex or age. Overall, 58.4% of all cases of recurrence 
were caused by NSAIDs (62.4% to different cyclooxygenase 
[COX] 1 inhibitors and 37.6% to the same NSAID), 21.9% 
by antibiotics, and 11.8% by other drugs (3 by carboplatin, 
2 by proton pump inhibitors, 2 by systemic corticosteroids, 
1 by lidocaine, 1 by diosmin, and 1 by calcitonin). In 7.9% 
of cases, recurrence was induced by both NSAIDs and 
antibiotics.
Anaphylaxis recurrence due to NSAIDs was significantly 
more common (P=.036) and the probability of 2 or more 
episodes involving NSAIDs was 13.5% higher than with 
other drugs.
The patients with NSAID-induced anaphylaxis had a 
lower probability of admission to hospital after 1 episode 
(P<.001), an increased occurrence of associated respiratory 
and mucocutaneous symptoms (24.6%), and a decreased 
Table 1. Causes of Drug-Induced Anaphylaxis in 313 Patients by Age Groupa
Drugs  All Patients Patients <18 y Patients 18-65 y Patients ≥65 y 
 (n=313) (n=26) (n=250) (n=37)
NSAIDs 150 (47.9) 11 (42.3) 124 (49.6) 15 (40.5)
Antibiotics 111 (35.5) 12 (46.2) 91 (36.4) 8 (21.6)
Anesthetic agents  19 (6.1) 0 15 (6) 4 (10.8)
Cytostatics  9 (2.9) 1 (3.8) 4 (1.6) 4 (10.8) 
(carboplatin, 4; oxaliplatin, 3;  
docetaxel, 1; tamoxifen, 1)
Corticosteroids  5 (1.6) 1 (3.8) 3 (1.2) 1 (2.7) 
(hydrocortisone, 2;      
methylprednisolone, 2;  
betamethasone, 1)
Analgesics (clonixin) 5 (1.6) 0 5 (2) 0
PPIs 
(lansoprazole, 1; omeprazole 1;  4 (1.3) 0 4 (1.6) 0 
pantoprazole, 1;   esomeprazole, 1)   
Vitamins 4 (1.3) 0 2 (0.8) 2 (5.4) 
(vitamin B12, 3; vitamin D3, 1)    
Iodinated contrast media 3 (0.96) 0 1 (0.4) 2 (5.4)
Vaccines  2 (0.6) 1 (3.8) 1 (0.4) 0 
(anti-tetanus in 1 adult; MMR and      
anti-meningococcal in 1 child) 
Othersb  10 (3.2) 0 8 (3.2) 2 (5.4)
Abbreviations: MMR, measles, mumps, and rubella vaccine; NSAIDs, nonsteroidal anti-inflammatory drugs; PPI, proton pump inhibitor. 
aData are presented as number (%) of patients in each group.
bAtropin, 2; calcitonin, 1; patent blue V, 1; diosmin, 1; hydroxyzine, 1; metoclopramide, 1; colloidal infusion, 1; ranitidine, 1; sulfasalazine,1. 
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Table 2. Drugs Responsible for NSAID-Induced Anaphylaxisa
NSAIDs  All Patients Patients <18 y Patients ≥18 y 
 (n=150) (n=11) (n=139)
Preferential COX-1 inhibitors   
ASA 55 (36.7)  4 (36.4) 51 (36.7)
Diclofenac 40 (26.7) 0 40 (28.8)
Ibuprofen 37 (24.7) 7 (63.6) 30 (21.6)
Metamizole 13 (8.7) 0 13 (9.4)
Other 
(aceclofenac, 1; ketoprofen, 2; ketorolac, 2; dexibuprofen, 1; 10 (6.7) 0 10 (7.2) 
fentiazac, 1; flurbiprofen, 1; naproxen, 1; propyphenazone, 1)   
Weak COX-1 inhibitors   
Paracetamol 2 (1.3) 2 (18.2) 0
Preferential/selective COX-2 inhibitors
Nimesulide 6 (4) 0 6 (4.3)
Coxibs 2 (1.3) 0 2 (1.4) 
(parecoxib, 1; etoricoxib, 1)
Abbreviations: ASA, acetylsalicylic acid; COX, cyclooxygenase; NSAID, nonsteroidal anti-inflammatory drug. 
aData are presented as number (%) of patients in each group.
Table 3. Drugs Responsible for Antibiotic-Induced Anaphylaxisa
Antibiotics  All Patients Patients <18 y Patients ≥18 y 
   (n=111) (n=12) (n=99)
β-Lactam antibiotics  90 (81.1) 12 (100) 78 (78.8)
 1. Penicillins  67 (60.4) 7 (58.3) 60 (60.6)
  1.1. Benzylpenicillins 11 (9.9) 0 11 (11.1)
  1.2. Aminopenicillins 52 (46.8) 6 (50) 46 (46.5) 
  (amoxicillin, 34; amoxicillin + clavulanic acid, 16; ampicillin, 2)   
  1.3. Isoxazolyl penicillins 4 (3.6) 1 (8.3) 3 (3) 
  (flucloxacillin)   
 2. Cephalosporins 23 (20.7) 4 (33.3) 19 (19.2)
  2.1. First-generation  15 (13.5) 0 15 (15.2) 
  (cefazolin, 13; cefatrizine, 1; cephradine, 1)   
  2.2. Second-generation  3 (2.7) 1 (8.3) 2 (2) 
  (cefuroxime, 2; cefoxitin, 1)   
  2.3. Third-generation  5 (4.5) 3 (25) 2 (2) 
  (ceftriaxone, 4; ceftazidime, 1)   
Quinolones 13 (11.7) 0 13 (13.1) 
(ciprofloxacin,7; moxifloxacin,5; levofloxacin, 1)   
Macrolides 3 (2.7) 0 3 (3) 
(clarithromycin, 2; spiramycin, 1)   
Sulphonamides 3 (2.7) 0 3 (3) 
(cotrimoxazole)   
Other 2 (1.8) 0 2 (2) 
(minocycline, 1; vancomycin, 1)
aData are presented as number (%) of patients in each group.
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rate of cardiovascular symptoms (16.6%). The frequency 
of cardiovascular symptoms in anaphylaxis episodes due to 
general anesthetics was 37.6% (Table 5).
On analyzing the most severe reactions (those in which 
there was involvement of 3 or more systems), there were no 
significant differences for atopy, age, number of episodes, 
severity of reaction, or involvement of NSAIDs, β-lactam 
antibiotics, or general anesthetics. 
Discussion
It is difficult to compare results among epidemiological 
studies of anaphylaxis primarily because of differences in study 
populations, diagnostic criteria, and notification methodology. 
There is also a paucity of epidemiological studies focusing on 
drug-induced anaphylaxis only. 
In our study, the prior standardization of international 
diagnostic criteria in drug-induced anaphylaxis applied by 
allergology and clinical immunology specialists allowed a 
more uniform methodology. 
Similarly to other authors, we found more cases of 
drug-induced anaphylaxis in adults and females, and also a 
predominance of males in cases seen in children under 18 
years of age [9,10].
The lower rate of hypersensitivity reactions to drugs 
seen in children and adolescents (8%) can be partly 
explained by lower exposure and differences in mechanisms 
of immunological response. Rubio et al [17] found a 
1.5-increased risk of hypersensitivity reactions to drugs 
in adults compared with children, but similar rates of 
anaphylaxis in the 2 age groups.
NSAIDs were the main cause of drug-induced anaphylaxis 
in our series, coinciding with reports from other outpatient 
studies [6,18-20] but also contrasting with findings by 
Cianferoni et al [10], who reported that NSAIDs were the 
second most common cause, after antibiotics. 
The estimated risk of penicillin-induced anaphylaxis 
among the general population in the United States is high, 
with ranges between 0.7% and 10% [21,22]. In our series, the 
number of cases of antibiotic-induced anaphylaxis in children 
was slightly higher than that of NSAID-induced anaphylaxis, 
and lower than that seen in other series [23,24].
It is generally agreed that preferential COX-1 inhibitors 
are the main type of NSAID involved in anaphylaxis. In 
our study, acetylsalicylic acid, diclofenac, and ibuprofen 
accounted for 88% of all such cases. In a study by Quiralte 
et al [25], naproxen, diclofenac, and ibuprofen were reported 
to carry a higher risk of anaphylactic reactions than other 
NSAIDs. 
Table 5. Regression Analysis of Probability of Clinical Symptoms and Recurrence of Anaphylaxis by 3 Main Groups of Drugs
 NSAIDs β-Lactam Antibiotics General Anesthetics 
 dy/dx  dy/dx   dy/dx 
Respiratory symptoms 15.5%a −8.4% −8.8%
Respiratory and mucocutaneous symptoms 24.6%b −1.6% −13.1%
Cardiovascular symptoms −16.6% 7.8 37.6%b
Recurrence of anaphylaxis  13.5%c −5.0% −17%
Table 4. Characterization of Anaphylaxis by 3 Main Groups of Drugs
Drugs Mean (SD) Age,  Sex Asthma, Atopy,  Mean Time to 
 y (Range)   % of Patients % of Patients Reaction (Range)
NSAIDs 43.0 (16.6)  F: 59% 27.0 47.5 30 min
(n=150) (3-89) M: 41%   (5 min-8 h)
  Ratio: 1.5:1   
β-Lactam antibiotics 39.9 (18.2) F: 74% 16.9 47.8 15 min 
(n=90) (4-82) M: 26%   (5 min-5 h) 
  Ratio: 2.9:1
General anesthetics 52.9 (17.3) F: 82% 0 20.0 Immediatea
(n=17) (18-78) M: 18% 
  Ratio: 4.7:1
Abbreviation: dy/dx, marginal effect in the increase of x over y; NSAID, nonsteroidal anti-inflammatory drug.
aP=.005.  
bP<.001. 
cP=.036.
Abbreviations: F, female; M, male; NSAIDs, nonsteroidal anti-inflammatory drugs.
aAll 17 patients experienced intraoperative anaphylaxis.
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Pyrazoline derivatives, and metamizole in particular, are 
considered to be the main NSAIDs responsible for immediate-
onset anaphylaxis [19]. In our population only 8.7% of NSAID-
induced anaphylactic reactions were related to metamizole. 
We did not find a higher prevalence of atopy or more severe 
reactions in patients who reacted to metamizole compared 
with those who reacted to other NSAIDs, unlike Sanches-
Borges et al [26], who reported that 69.2% of such patients 
were atopic and that 72.7% had more severe reactions.
Adverse reactions to selective or preferential COX-2 
inhibitor NSAIDs and paracetamol are rare, and these drugs are 
considered an alternative in cases of anaphylaxis to preferential 
COX-1 inhibitors [19,25]. Their increased use may explain the 
number of anaphylaxis cases related to nimesulide, selective 
COX-2 inhibitors, and paracetamol, which in our series 
accounted for 6% of all NSAID-induced episodes.
Some authors have found that NSAID-anaphylactic reactions 
are mainly specific to a particular drug or group of drugs [25,26]. 
In our study, however, a majority of patients (62%) had recurrent 
anaphylaxis to NSAIDs from distinct pharmacological groups, 
suggesting that a specific immunological mechanism is unlikely. 
Diclofenac was associated with a surprisingly high number of 
cases of recurrence to the same NSAID. However, unlike Asero 
et al [27], we did not have information on acetylsalicylic acid 
challenge tests to define cases of selective hypersensitivity to 
a single NSAID.
 In agreement with previous reports, we found a higher rate of 
anaphylaxis to β-lactam antibiotics (81.1%) than to non-β-lactam 
antibiotics, which are rarely implicated in anaphylaxis [3]. There 
was a high rate of anaphylaxis to β-lactam penicillins (60.4%), 
and more cases due to aminopenicillins and cephalosporins 
than to benzylpenicillins; in this respect our results are similar 
to those seen by Blanca Gomez et al [28]. In our population, 
cefazolin was responsible for anaphylaxis in 56.5% of 
patients allergic to cephalosporins. This high number of 
cases might be due to the frequent use of this antibiotic in 
Portugal, particularly as prophylaxis in surgical protocols. 
Changes in β-lactam prescription patterns in Europe may 
explain the increase in anaphylactic reactions to amoxicillin 
and cephalosporins and the decrease in penicillin-related 
cases in recent years, although few epidemiological studies 
have provided supporting data [28]. 
We highlight the high proportion of anaphylaxis cases 
induced by quinolone (11.7%). Similar rates were reported by 
Moneret-Vautrin et al [13] and may reflect the increasing use 
of quinolone antibiotics in the last decade.
Specialized studies in different countries have shown that 
NMBAs are a leading cause of intraoperative anaphylaxis 
[10,29]. In our series, they were the third most common 
cause of anaphylaxis. In a study by Faria et al [30] NMBAs 
were identified as inducers of anaphylaxis in 62.5% of cases, 
and the authors highlighted the high rate of moderate and 
severe episodes.
Severe reactions attributed to ICM have decreased with 
the reduction in use of high-osmolarity ionic formulations. 
In a European study carried out by Brockow et al [31] in 220 
patients with a hypersensitivity reaction to ICM, 8.5% had 
grade II or III anaphylaxis [31]. We observed a low rate of 
anaphylaxis to ICM in our population (0.96%).
Of the remaining drug groups, anaphylactic reactions to 
systemic corticosteroids and cytostatics, particularly platinum-
based chemotherapeutic agents, were the most frequent. 
Because these are core drugs that are not always replaceable, 
desensitization must be considered in some cases.
No cases of anaphylaxis to new treatments such as 
biological modifiers and monoclonal antibodies were 
reported.
In 94% of our patients, the symptoms occurred within the 
first 2 hours. Interestingly, all 4 anaphylactic reactions that 
occurred between 2 and 8 hours were related to weak COX-1 
inhibitors (nimesulide, paracetamol, and etoricoxib). This may 
be because there are non-immunological mechanisms at play 
that are not completely understood or because initial symptoms 
were misinterpreted or underestimated.
Mucocutaneous symptoms are common in anaphylaxis 
although the absence of these symptoms does not rule out 
anaphylaxis, and it is important to pay attention to other early 
extracutaneous symptoms in the clinical diagnosis [3]. In our 
series, mucocutaneous symptoms were observed in 7.8% of 
cases. On comparing the involvement of 3 or more systems 
between the 3 main drug groups (NSAIDs, β-lactams, and 
NMBAs), the risk of respiratory and mucocutaneous symptoms 
would appear to be higher in anaphylaxis due to NSAIDs, while 
that of cardiovascular symptoms would appear to be lower. 
By contrast, in the case of anaphylaxis induced by general 
anesthesia, there appears to be a higher risk of cardiovascular 
symptoms. Unlike Pumphrey et al [14], we did not find a high 
rate of cardiovascular collapse in elderly patients.
Atopy was not a significant risk factor for anaphylaxis in 
any of the 3 main drug groups; our findings in this respect are 
similar to those of other authors [3,18].
A high risk of anaphylaxis has been reported in individuals 
with asthma, and severe asthma has been associated with a high 
risk of fatal outcome [3,14]. Studies performed in the United 
Kingdom and the United States found a 5.3%-increased risk 
of drug anaphylaxis in asthmatics [32]. In our series, 18.8% 
of patients were asthmatics, and the majority had anaphylaxis 
to NSAIDs. 
There are few studies on risk factors for recurrent drug 
anaphylaxis. The recurrence rate in our series was 25.6%, 
which is lower than rates seen in the 1980s and 1990s in 
the United States [20]. The rate of recurrence of NSAID-
induced anaphylaxis was particularly high (>13.5%), possibly 
because the treating physician and/or the patient may have 
underestimated the severity of the initial episode, leading to 
a failure to identify the causal agent. This would have led to 
a high risk of subsequent administration of the same drug or 
another drug from the same pharmacological group, due to 
a lack of knowledge of cross-reactivity mechanisms among 
patients and even physicians.
In a recent Australian study, Mullins [18] found severe 
symptoms during the initial anaphylaxis episode to be a 
predictive factor of recurrence of anaphylaxis. We did not 
observe this to be the case in our study.
We did not evaluate the use of concomitant medication, 
the condition under treatment, or the circumstances in which 
the episode occurred. Accordingly, we were unable to evaluate 
co-factors that potentially amplify anaphylaxis [10].
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Although anaphylaxis is potentially fatal, only a quarter of 
the patients with drug-induced anaphylaxis in our series were 
seen in an emergency department, and a third of these were 
admitted to hospital. 
Epinephrine is the first-line life-saving treatment in 
anaphylactic reactions, with a proven association between 
increased mortality and increased refractory or biphasic 
anaphylaxis if administration is delayed or omitted [3,4]. Under 
half of the patients in our series were treated with epinephrine. 
This rate is similar to that reported by other studies [33], but 
lower than reported more recently by Brown et al (57%) [34] 
and Pumphrey (62%) [14].
There was a very low rate of prescription of epinephrine 
auto-injectors, but it was significantly higher in children 
and adolescents, particularly at younger ages. This may be 
because physicians are more concerned with preventing onset 
of anaphylaxis in children and adolescents than in adults. The 
underprescription of epinephrine auto-injectors in cases of 
anaphylaxis is well-known, and also holds for Portugal, as 
shown by Branco Ferreira et al [35].
In the case of drug-induced anaphylaxis, once the risk 
has been identified, prescribing epinephrine auto-injectors 
can be a matter of debate, particularly in cases of anaphylaxis 
to diagnostic or treatment agents used exclusively in 
hospitals, such as general anesthetic agents, cytostatics, or 
ICM. Epinephrine should be prescribed in cases of severe 
anaphylaxis because it can transmit a feeling of safety and 
minimize the fear of drug administration that is common in 
patients who have previously had a sense of imminent death.
Conclusions
Drugs are considered to be the main trigger of anaphylaxis, 
particularly in adults. Prescription patterns and genetic, 
environmental, or unidentified co-factors may influence the rate 
of drug-induced anaphylaxis in different populations. However, 
there seems to be consensus that NSAIDs, antibiotics, NMBAs, 
and cytostatics are the main drugs responsible for inducing 
anaphylaxis.
As anaphylaxis is unpredictable and potentially fatal, its 
recognition and prevention is vital. Early administration of 
epinephrine is of extreme importance as relapses are common. We 
highlight the need for urgent referral to an allergist for a correct 
diagnosis following the first episode. The allergist plays a vital 
role in the identification of the culprit drug, the recommendation 
of safe alternatives, and the transmission of information to the 
patient and his/her physician and health care team. 
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